Study of Surgery in Patients With Idiopathic Macular Hole

NCT ID: NCT02905409

Last Updated: 2019-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

228 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effects of two different internal limiting membrane peeling with distinct diameters after macular hole surgery on anatomical closure grades.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to investigate two distinct diameter of internal limiting membrane peeling on anatomical outcomes of macular hole surgery with different preoperative idiopathic macular hole.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Macular Hole Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4PD diameter of ILM peeling in surgery

Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI\<0.5, 0.5≤MHCI\<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.

Group Type ACTIVE_COMPARATOR

ILM peeling surgery

Intervention Type PROCEDURE

4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)

2PD diameter of ILM peeling in surgery

Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI\<0.5, 0.5≤MHCI\<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.

Group Type EXPERIMENTAL

ILM peeling surgery

Intervention Type PROCEDURE

4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ILM peeling surgery

4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with IMH
* patients signed the ICF
* patients with course of IMH less than 3 years

Exclusion Criteria

* patients with hyper myopia
* patients with traumatic macular hole
* accompanied or secondary of other fundus disease
* open or reopen after receiving MH surgery
* patients with retinal detachment
* received vitrectomy due to other diseases
* glaucoma cannot be controled by medication
* patients with other retinal or choroidal disease that may affect VA
* poor patients compliance
* poor condition that cannot undertake the surgery
* dioptric media opacities which make it difficult to exam fundus or measure on OCT
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Tongren Hospital

OTHER

Sponsor Role collaborator

Beijing Hospital

OTHER_GOV

Sponsor Role collaborator

Peking Union Medical College Hospital

OTHER

Sponsor Role collaborator

Peking University People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mingwei Zhao

Head of Opthalmology Department, Principal Investigator, Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mingwei Zhao, M.D

Role: STUDY_DIRECTOR

Peking University People's Hospital

Hong Dai, M.D

Role: PRINCIPAL_INVESTIGATOR

Peking Union Medical College

Wenbin Wei, M.D

Role: PRINCIPAL_INVESTIGATOR

Beijing Tongren Hospital of Capital Medical University

Youxin Chen, M.D

Role: PRINCIPAL_INVESTIGATOR

Peking Union Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

People's Hospital of Peking University

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mingwei Zhao, M.D

Role: CONTACT

Phone: 13801057408

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Minwei Zhao, M.D

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILMIMH-CHINA

Identifier Type: -

Identifier Source: org_study_id